David Lebowitz
Stock Analyst at BMO Capital
(4.75)
# 649
Out of 5,058 analysts
479
Total ratings
58%
Success rate
13.4%
Average return
Main Sectors:
Stocks Rated by David Lebowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCAX Bicara Therapeutics | Reiterated: Buy | $35 | $17.62 | +98.64% | 2 | Oct 7, 2026 | |
| BMRN BioMarin Pharmaceutical | Reiterated: Buy | $97 | $56.05 | +73.06% | 25 | Oct 6, 2026 | |
| PRME Prime Medicine | Reiterated: Buy | $9 | $3.61 | +149.31% | 2 | Sep 24, 2026 | |
| IONS Ionis Pharmaceuticals | Reiterated: Hold | $54 | $44.12 | +22.39% | 53 | Sep 23, 2026 | |
| ALNY Alnylam Pharmaceuticals | Reiterated: Buy | $318 | $234.03 | +35.88% | 58 | Sep 17, 2026 | |
| ASND Ascendis Pharma | Reiterated: Buy | $319 | $226.62 | +40.76% | 41 | Sep 14, 2026 | |
| CATX Perspective Therapeutics | Reiterated: Buy | $11 | $2.34 | +370.09% | 2 | Sep 14, 2026 | |
| EXEL Exelixis | Reiterated: Hold | $54 | $62.83 | -14.05% | 19 | Sep 11, 2026 | |
| AKTS Aktis Oncology | Initiated Coverage: Buy | $37 | $16.01 | +131.11% | 1 | Aug 18, 2026 | |
| COGT Cogent Biosciences | Reiterated: Buy | $22 | $29.51 | n/a | 13 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $17 | $58.50 | n/a | 17 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $77 → $84 | $63.92 | n/a | 6 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $67 | $67.13 | n/a | 21 | Sep 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 → $48 | $28.93 | n/a | 5 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $38 → $29 | $27.37 | n/a | 4 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $505 | $459.81 | n/a | 14 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $72 → $89 | $82.39 | n/a | 22 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $35 → $20 | $25.48 | n/a | 22 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1.5 → $1.7 | $0.9724 | n/a | 15 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $10 → $12 | $11.34 | n/a | 19 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $88 → $103 | $113.27 | n/a | 21 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $32 → $45 | $60.99 | n/a | 23 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $3 → $2.75 | $0.6955 | n/a | 5 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $12 → $14 | $3.77 | n/a | 15 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $29 → $27 | $0.3508 | n/a | 3 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $20 → $21 | $13.65 | n/a | 13 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $29 → $25 | $21.30 | n/a | 8 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $39 | $3.64 | n/a | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $57 → $54 | $87.97 | n/a | 11 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $52 → $50 | $29.10 | n/a | 2 | Jul 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $15 → $17 | $3.37 | n/a | 11 | Apr 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $20 | $0.0001 | n/a | 3 | Dec 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $60 | $17.79 | n/a | 1 | Oct 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $126 | $508.75 | n/a | 1 | Jan 9, 2015 |
Bicara Therapeutics
Oct 7, 2026
Reiterated: Buy
Price Target: $35
Current: $17.62
Upside: +98.64%
BioMarin Pharmaceutical
Oct 6, 2026
Reiterated: Buy
Price Target: $97
Current: $56.05
Upside: +73.06%
Prime Medicine
Sep 24, 2026
Reiterated: Buy
Price Target: $9
Current: $3.61
Upside: +149.31%
Ionis Pharmaceuticals
Sep 23, 2026
Reiterated: Hold
Price Target: $54
Current: $44.12
Upside: +22.39%
Alnylam Pharmaceuticals
Sep 17, 2026
Reiterated: Buy
Price Target: $318
Current: $234.03
Upside: +35.88%
Ascendis Pharma
Sep 14, 2026
Reiterated: Buy
Price Target: $319
Current: $226.62
Upside: +40.76%
Perspective Therapeutics
Sep 14, 2026
Reiterated: Buy
Price Target: $11
Current: $2.34
Upside: +370.09%
Exelixis
Sep 11, 2026
Reiterated: Hold
Price Target: $54
Current: $62.83
Upside: -14.05%
Aktis Oncology
Aug 18, 2026
Initiated Coverage: Buy
Price Target: $37
Current: $16.01
Upside: +131.11%
Cogent Biosciences
Sep 4, 2025
Reiterated: Buy
Price Target: $22
Current: $29.51
Upside: n/a
Sep 3, 2025
Reiterated: Hold
Price Target: $17
Current: $58.50
Upside: n/a
Sep 3, 2025
Reiterated: Buy
Price Target: $77 → $84
Current: $63.92
Upside: n/a
Sep 1, 2025
Reiterated: Buy
Price Target: $67
Current: $67.13
Upside: n/a
Aug 20, 2025
Reiterated: Buy
Price Target: $70 → $48
Current: $28.93
Upside: n/a
Aug 20, 2025
Reiterated: Hold
Price Target: $38 → $29
Current: $27.37
Upside: n/a
Aug 19, 2025
Rated: Buy
Price Target: $505
Current: $459.81
Upside: n/a
Aug 18, 2025
Reiterated: Buy
Price Target: $72 → $89
Current: $82.39
Upside: n/a
Aug 15, 2025
Downgraded: Hold
Price Target: $35 → $20
Current: $25.48
Upside: n/a
Aug 11, 2025
Reiterated: Hold
Price Target: $1.5 → $1.7
Current: $0.9724
Upside: n/a
Aug 8, 2025
Reiterated: Hold
Price Target: $10 → $12
Current: $11.34
Upside: n/a
Jul 30, 2025
Reiterated: Buy
Price Target: $88 → $103
Current: $113.27
Upside: n/a
Feb 11, 2025
Reiterated: Sell
Price Target: $32 → $45
Current: $60.99
Upside: n/a
Nov 5, 2021
Reiterated: Hold
Price Target: $3 → $2.75
Current: $0.6955
Upside: n/a
Oct 12, 2021
Reiterated: Hold
Price Target: $12 → $14
Current: $3.77
Upside: n/a
Oct 12, 2021
Reiterated: Buy
Price Target: $29 → $27
Current: $0.3508
Upside: n/a
Oct 12, 2021
Reiterated: Hold
Price Target: $20 → $21
Current: $13.65
Upside: n/a
Oct 12, 2021
Reiterated: Buy
Price Target: $29 → $25
Current: $21.30
Upside: n/a
Aug 24, 2021
Initiated Coverage: Hold
Price Target: $39
Current: $3.64
Upside: n/a
Aug 3, 2021
Reiterated: Buy
Price Target: $57 → $54
Current: $87.97
Upside: n/a
Jul 16, 2021
Reiterated: Buy
Price Target: $52 → $50
Current: $29.10
Upside: n/a
Apr 30, 2021
Reiterated: Sell
Price Target: $15 → $17
Current: $3.37
Upside: n/a
Dec 7, 2020
Reiterated: Hold
Price Target: $20
Current: $0.0001
Upside: n/a
Oct 2, 2017
Upgraded: Buy
Price Target: $60
Current: $17.79
Upside: n/a
Jan 9, 2015
Initiated Coverage: Hold
Price Target: $126
Current: $508.75
Upside: n/a